Natixis Axsome Therapeutics, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Natixis holds 890 shares of AXSM stock, worth $82,921. This represents 0.0% of its overall portfolio holdings.
Number of Shares
890
Previous 33,652
97.36%
Holding current value
$82,921
Previous $2.71 Million
97.08%
% of portfolio
0.0%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding AXSM
# of Institutions
326Shares Held
37.7MCall Options Held
912KPut Options Held
855K-
Rtw Investments, LP New York, NY4.19MShares$390 Million6.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4MShares$372 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$307 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA2.36MShares$220 Million34.46% of portfolio
-
Bvf Inc San Francisco, CA1.05MShares$97.5 Million2.99% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $3.99B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...